TheraBionic P1: A New Systemic Targeted Therapy for Advanced HCC

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Boris Pasche, MD, PhD, of Karmanos Cancer Institute gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced hepatocellular carcinoma. He discusses the trial that led to the device’s regulatory approval by the FDA, and compares it to existing treatments for advanced HCC in terms of efficacy, safety, and patient quality of life.